<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119339</url>
  </required_header>
  <id_info>
    <org_study_id>H553000-1001</org_study_id>
    <secondary_id>2010-018355-10</secondary_id>
    <nct_id>NCT01119339</nct_id>
  </id_info>
  <brief_title>Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis</brief_title>
  <official_title>An Investigator-blind, Controlled Study to Assess the Efficacy of Six Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004&#xD;
      in a Psoriasis Plaque Test (PPT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in skin thickness</measure>
    <time_frame>15 days</time_frame>
    <description>measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in clinical score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in erythema score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in induration score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in scaling score</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of skin reactions per patient as a measure of safety and tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>scoring will be performed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events per patients as a measure of safety and tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>reporting will be performed by investigator</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS 41004 dosage 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004</intervention_name>
    <description>LAS 41004 dosage 1, once daily</description>
    <arm_group_label>LAS 41004 dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004</intervention_name>
    <description>LAS 41004 dosage 2, once daily</description>
    <arm_group_label>LAS 41004 dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004</intervention_name>
    <description>LAS 41004 dosage 3, once daily</description>
    <arm_group_label>LAS 41004 dosage 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004</intervention_name>
    <description>LAS 41004 dosage 4, once daily</description>
    <arm_group_label>LAS 41004 dosage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004</intervention_name>
    <description>LAS 41004 , dosage 5, once daily</description>
    <arm_group_label>LAS 41004 dosage 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS 41004 dosage 6</intervention_name>
    <description>LAS 41004, dosage 6, once daily</description>
    <arm_group_label>LAS 41004 dosage 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Reference, once daily</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 18 and 75 years of age with a diagnosis of stable&#xD;
             plaque-type psoriasis (psoriasis vulgaris) for at least 6 month&#xD;
&#xD;
          -  Psoriasis plaques that are suitable to be defined as target area lesions by the&#xD;
             following criteria:&#xD;
&#xD;
               1. Psoriasis plaques must be located at trunk and/or extremities. Plaques that are&#xD;
                  located on the head (incl. scalp), palms, sole of the feet, intertriginous or&#xD;
                  genitoanal areas are not suitable as target areas&#xD;
&#xD;
               2. Comparable psoriasis plaques with at least &quot;2&quot; in each score (Range 0-4) for the&#xD;
                  three distinct symptoms scaling; erythema; and induration&#xD;
&#xD;
               3. No more than 3 points difference in total score (= sum of scores for scaling,&#xD;
                  erythema and induration; Range 0-12) of the chosen comparable psoriasis plaques&#xD;
&#xD;
               4. Enough psoriatic surface area to define 8 clearly distinguishable (minimum&#xD;
                  distance between test areas: 1cm) test areas of at least 1 cmÂ² plaque size&#xD;
&#xD;
          -  Patient is willing and able to comply with the requirements of the clinical study&#xD;
             protocol. In particular, patient must adhere to concomitant therapy prohibitions of&#xD;
             the test areas and must agree to avoid intense UV exposure of the test areas during&#xD;
             the study&#xD;
&#xD;
          -  Written informed consent to participate in the study, prior to any study related&#xD;
             procedures, indicating an understanding of the purpose of the study&#xD;
&#xD;
          -  A patient of childbearing potential agrees to use one of the following contraceptive&#xD;
             methods for the duration of the study:&#xD;
&#xD;
               1. Strict abstinence (exception: male partner with a vasectomy for at least 3 months&#xD;
                  prior to study entry is allowed)&#xD;
&#xD;
               2. Combined oral, implanted or injectable contraceptives on a stable dose for at&#xD;
                  least 3 months prior to study entrance&#xD;
&#xD;
               3. Intrauterine device (IUD) inserted for at least 1 month prior to study entrance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Too few body surface area covered with psoriasis plaques that meet the specified&#xD;
             inclusion criteria to be defined as 8 clearly distinguishable test areas&#xD;
&#xD;
          -  Any condition that may interfere with the study assessments or sonographic&#xD;
             measurements of the skin and/or may have an influence on skin immune response (incl.&#xD;
             open wounds)&#xD;
&#xD;
          -  Known adverse reactions of any severity or hypersensitivity to any ingredient of the&#xD;
             test products&#xD;
&#xD;
          -  No willingness to avoid induction of heavy sweating, e.g. due to sauna visits,&#xD;
             excessive sports activities during the study course&#xD;
&#xD;
          -  No willingness to avoid swimming, bathing or wetting of the designated test areas&#xD;
             between visits&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  A medical condition that may put the patient at a general risk and therefore would&#xD;
             prevent participation in the clinical trial (including but not limited to: serious&#xD;
             infectious diseases, major surgery within the last 4 weeks, coronary artery disease,&#xD;
             renal impairment, hepatic impairment, uncontrolled metabolic diseases, disorders of&#xD;
             the calcium metabolism, autoimmune diseases)&#xD;
&#xD;
          -  History or presence of malignant disease (other than surgically removed basal cell&#xD;
             carcinoma) and/or auto immune diseases&#xD;
&#xD;
          -  Current diagnosis of guttate, erythrodermic or pustular psoriasis&#xD;
&#xD;
          -  Patients who did not respect the following wash-out periods prior or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Willers, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Almirall Hermal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <name_title>Christoph Willers, MD, MBA</name_title>
    <organization>Almirall Hermal GmbH</organization>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>topical</keyword>
  <keyword>psoriasis plaques test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

